When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?
Crossref DOI link: https://doi.org/10.1038/bmt.2017.109
Published Online: 2017-06-05
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Solano, C
Giménez, E
Piñana, J L
Hernández-Boluda, J C
Amat, P
Vinuesa, V
Navarro, D
Text and Data Mining valid from 2017-06-05
Version of Record valid from 2017-06-05
Article History
First Online: 5 June 2017
Competing interests
: The authors declare no conflict of interest.